The presentation will discuss recent advancements in the area of cancer model development utilizing 3D bioprinting technologies for immuno-oncology applications. Physiologically relevant 3D cancer models are critical for drug discoveries. These 3D cancer models predict the outcome of in vivo experiments that 2D models often fail. The use of 3D cell culture, aided by CELLINK’s bioprinting technologies, affords the use of multicellular constructs in the presence of tissue-specific extracellular matrix to better mimic the in vivo milieu. In this presentation, Dr. Nath will discuss the droplet tumor printing technology for the evaluation of immune checkpoint drugs and how the technology can be used for personalized medicine.